# Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris

> **NCT06905210** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 526 (estimated)

## Conditions studied

- Acne Vulgaris
- Acne Vulgaris on the Face

## Interventions

- **DRUG:** Placebo of the experimental drug
- **DRUG:** Experimental drug

## Key facts

- **NCT ID:** NCT06905210
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-02
- **Final completion:** 2027-03
- **Target enrollment:** 526 (ESTIMATED)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905210, "Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06905210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*